Analyst Price Target is $28.25
▲ +409.93% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Biomea Fusion in the last 3 months. The average price target is $28.25, with a high forecast of $60.00 and a low forecast of $5.00. The average price target represents a 409.93% upside from the last price of $5.54.
Current Consensus is
Moderate Buy
The current consensus among 8 polled investment analysts is to moderate buy stock in Biomea Fusion. This Moderate Buy consensus rating has held steady for over two years.
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Read More